Abstract A2-17: High expression of CDK6 confers resistance to fulvestrant in breast cancer cells and is a potential predictor of fulvestrant treatment failure in estrogen receptor-positive breast cancer
Cancer Res (2015) 75 (22_Supplement_1): A2-17.
Currently there are no citedby results. Try again later.
